Sep 3, 2026 · 12 min
Personalized vaccines target melanoma’s return
What an mRNA melanoma vaccine may mean for cancer treatment
The approach could make cancer vaccination more precise, but its benefits, risks, cost, and availability remain unsettled.
- 1Each vaccine uses mutations from a patient’s tumor to train an individualized immune response.
- 2The trial paired the vaccine with Keytruda, building on an established treatment rather than replacing it.
- 3Early results and tolerability are encouraging, but phase-three data and regulatory decisions will determine broader access.
Don't miss
Michael A. Postow lays out how a tumor’s mutations become the blueprint for an individualized vaccine.
The brief
Science Friday examines a personalized mRNA vaccine designed to reduce melanoma recurrence when paired with Keytruda, the existing standard of care.
Michael A. Postow explains the bespoke process: doctors remove and sequence a tumor, then use algorithms to identify mutations for a patient-specific vaccine.
Melanoma became an early testing ground because it is especially visible to the immune system and has already responded to immunotherapy.
The vaccine is not presented as a replacement for Keytruda; the trial tests whether immune priming and checkpoint inhibition work better together.
Preliminary findings suggest improvements in recurrence-free and distant metastasis-free survival, while side effects, manufacturing time, phase-three data, and access remain open questions.
Featuring
Michael A. Postow
KeytrudaListen to the full episode and explore every guest, topic, and moment on PodLume.